Clinical Trials Logo
  1. Home
  2. Stage IIIC Melanoma
  3. NCT06190249

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Stage IIIC Melanoma Clinical Trial

Official title:
A Phase I Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN144) With Adjuvant Pembrolizumab for Treatment of Immunotherapy Naïve Patients With High Risk Stage IIIb-dResectable Melanoma

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of adjuvant adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin-2 (IL-2) after a nonmyeloablative lymphodepletion (NMA-LD) preparative regimen, followed by Pembrolizumab.

Clinical Trial Description

Primary: • To evaluate the efficacy of LN-144 with adjuvant Pembrolizumab in Stage IIIb-d melanoma patients as assessed by 6 and 12-month relapse-free survival (RFS) Secondary: - To further evaluate the efficacy of LN-144 with adjuvant Pembrolizumab in Stage IIIb-d melanoma patients using overall survival (OS) and distant metastasis-free survival - To characterize the safety profile of LN-144 in Stage IIIb-d melanoma patients as measured by the incidence of Grade ≥ 3 treatment emergent adverse events (TEAEs) within 3 months of LN-144 administration - To identify location of relapse - Rate of achievable recruitment for duration of planned recruitment period ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06190249
Study type Interventional
Source Case Comprehensive Cancer Center
Contact
Status Suspended
Phase Phase 1
Start date June 30, 2024
Completion date July 2028
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT01216787 - RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery Phase 2
Active, not recruiting NCT01026324 - Dinaciclib in Treating Patients With Stage III-IV Melanoma Phase 1/Phase 2
Completed NCT01748747 - Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery Early Phase 1
Terminated NCT01316692 - Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma Phase 2
Terminated NCT02203604 - High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery Phase 2
Completed NCT02094872 - Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic Phase 2
Terminated NCT01835184 - Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery Phase 1
Terminated NCT02236546 - FDG-PET in Advanced Melanoma N/A
Completed NCT00085189 - Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma Phase 2
Completed NCT01127451 - Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma Phase 2
Active, not recruiting NCT01898403 - Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma N/A
Completed NCT00089063 - Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma Phase 2
Completed NCT02296112 - Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations Phase 2
Terminated NCT01701037 - Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery Phase 2
Terminated NCT01533948 - Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery Phase 2
Terminated NCT01519427 - Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib Phase 2
Completed NCT02166255 - APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery Phase 1
Completed NCT01321437 - Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma Phase 2
Completed NCT00436605 - Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma Phase 2
Withdrawn NCT02507076 - Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma N/A